Recall vs. Market Withdrawal vs. Stock Recovery: How FDA Classifies Corrective Actions and What Must Be Reported

Recall, market withdrawal, or stock recovery: how FDA draws the line and what must be reported

When a firm pulls or fixes a product that is already on the market, the label it applies to that action is not cosmetic. It determines whether the action is a recall subject to 21 CFR Part 7, whether it triggers a mandatory report to FDA, whether it appears in the public Enforcement Report, and what class of health hazard FDA will assign. The regulatory dividing lines turn on three questions: is the product marketed or still under the firm's control, is there a violation, and how serious is that violation.

The three categories under 21 CFR Part 7

FDA's recall regulations separate corrective actions into three mutually exclusive categories, distinguished mainly by whether the product has been distributed, whether it is violative, and how serious the violation is ⁶⁰⁹³⁷⁴.

Recall. A recall is "a firm's removal or correction of a marketed product that FDA considers to be in violation of the laws it administers and against which the Agency would initiate legal action, e.g., seizure." The definition expressly states that "recall does not include a market withdrawal or a stock recovery" ⁶⁰⁹³⁷⁴. So an action is a recall only when the product is marketed or distributed, is violative under an FDA-administered law, and the violation is serious enough that FDA would initiate legal action ⁶⁰⁹³⁷⁴.

Market withdrawal. A market withdrawal is "a firm's removal or correction of a distributed product which involves a minor violation that would not be subject to legal action by the Food and Drug Administration or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc." ⁹²⁶⁰⁹³. The product has been distributed, but the issue is either a minor violation not subject to FDA legal action or no violation at all ⁹²⁶⁰⁹³.

Stock recovery. A stock recovery is "a firm's removal or correction of a product that has not been marketed or that has not left the direct control of the firm, i.e., the product is located on premises owned by, or under the control of, the firm and no portion of the lot has been released for sale or use" ⁹¹⁶⁰. A stock recovery applies only to product that has not been marketed and is not a recall ⁹². Critically, if devices (or other product) have in fact been distributed and manifest violations, a recall is required even if the firm initially treated the situation as a stock recovery ⁹².

Removal versus correction

Within a recall, FDA further distinguishes the mechanics of the action. A correction is the repair, modification, adjustment, relabeling, destruction, or inspection of a product without its physical removal to another location ¹³⁹³. A removal is the physical removal of a product to another location for repair, modification, adjustment, relabeling, destruction, or inspection ¹³. Both can constitute a recall when the underlying product is marketed and violative.

Quick comparison

The practical test: a distributed product with a violation serious enough to invite FDA legal action is a recall; a distributed product with only a minor or no violation (routine stock rotation, equipment repair) is a market withdrawal; and product that never left the firm's control with no portion released is a stock recovery ^92609391. DAYTRANA, for example, appears in FDA records as a "non-safety-related voluntary market withdrawal," explicitly described as "not due to safety issues," which is how a market withdrawal is characterized as opposed to a recall taken because of a potential health or safety risk ^129131132.

Recall classification: Class I, II, and III

Once an action is a recall, FDA assigns a numerical class reflecting the relative degree of health hazard, based on a health hazard evaluation and the factors set out in 21 CFR 7.41 ⁶⁰:

• Class I — a situation in which there is a reasonable probability that use of, or exposure to, a violative product will cause serious adverse health consequences or death ^70747879.
• Class II — a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious health consequences is remote ^70747879.
• Class III — a situation in which use of, or exposure to, a violative product is not likely to cause illness or injury ^70747879.

The class is FDA's determination, made on the basis of the health hazard evaluation and in consideration of the 7.41 factors, not the firm's own label for the action ⁶⁰.

What must be reported, and when

Recalls generally

FDA recommends that a recalling firm notify the appropriate FDA Recall Coordinator as soon as it decides a recall is appropriate, and before it issues press or written customer notices ⁴⁸. For a voluntary recall where the firm believes the product is violative, the firm is requested to notify FDA immediately ⁴⁹. The date of the first communication to direct accounts or the public is the date of initiation of the recall ⁴⁹.

FDA expects the recall submission to include copies of issued or proposed recall communications, a clear identification of the distribution level to which the recall extends, and instructions to direct accounts to extend the recall downstream where further distribution occurred ⁴⁹. Recall communications themselves should state that the product is subject to recall, that further distribution or use should cease immediately, the reason for the recall and the hazard involved, specific handling instructions, a means for recipients to respond, and clear disposition instructions ⁵⁶⁵⁸. Recall Status Reports should generally cover the dates and method of customer notification, numbers of customers notified and responding, quantity returned or accounted for, estimated completion time, effectiveness-check details, and (as FDA recommends) the root cause and the corrective and preventive actions ⁵¹.

The device-specific trigger: 21 CFR Part 806

For medical devices, the reporting obligation is codified separately. Under 21 CFR Part 806, a device correction or removal must be reported to FDA within 10 working days from the time it is initiated if the action was taken to either reduce a risk to health posed by the device, or remedy a violation of the FD&C Act caused by the device that may present a risk to health ¹³⁵⁶⁸.

If the action is not reportable under Part 806, the firm must still keep records of the correction or removal ⁴⁶. The following are generally exempt from reporting (recordkeeping only, or excluded entirely) ²¹³¹⁶:

• actions to improve device performance or quality that do not reduce a risk to health or remedy an FD&C Act violation ²;
• market withdrawals ²;
• routine servicing ²¹³;
• stock recoveries ²;
• cybersecurity routine updates and patches addressing controlled-risk vulnerabilities, generally treated as device enhancements rather than Part 806 actions ¹⁶.

A Part 806 report is also not required where the same information has already been submitted under 21 CFR Part 803 (medical device reporting) or Part 1004 ⁶. In short, the Part 806 report is driven by the same "risk to health / violative condition that may present a risk to health" test that separates a recall from a market withdrawal or stock recovery ¹²⁶⁰.

Voluntary, FDA-requested, and mandatory recalls

Most recalls are voluntary. FDA generally gives the firm the first opportunity to develop and issue recall communications and public warnings, and the firm need not delay initiation while FDA reviews the strategy or communications ^57596649.

FDA may request a firm initiate a recall when the product presents a risk of illness or injury or gross consumer deception, the firm has not already initiated a recall, and agency action is necessary to protect the public health ⁶². Public notifications in the Enforcement Report identify recalls as FDA-requested or firm-initiated ⁵³⁶⁰.

Mandatory recall authority is statutory and product-specific:

• Food — section 423 of the FD&C Act, where FDA determines there is a reasonable probability the food is adulterated or misbranded and that use or exposure will cause serious adverse health consequences or death to humans or animals (SAHCODHA) ³⁰³⁴.
• Devices — section 518(e) of the FD&C Act authorizes FDA to order a mandatory recall ⁴¹.
• Cosmetics — section 611 of the FD&C Act authorizes FDA to order a responsible person to cease distribution and recall a cosmetic when the statutory criteria are met, with additional authorities under section 613 for cosmetics that are also drugs or devices ^36394038.

Procedurally, a mandatory recall differs from a voluntary one because FDA must first give the responsible party an opportunity to cease distribution and recall voluntarily; only if the party refuses or fails to comply does FDA proceed to an order (for food, with notice, an informal hearing within two days, and then a recall order if removal from commerce is necessary) ³⁰³⁶³⁹. Voluntary recalls proceed under 21 CFR Part 7, Subpart C ³².

Precedents in the Enforcement Report and recall databases

FDA's Enforcement Report and recall databases hold large volumes of classified precedents. Both drug and device recalls are well populated across all three classes, with Class II the most common category by count for each product type. Representative recent records include Class I drug recalls from Liebel-Flarsheim Company LLC, JB Chemicals and Pharmaceuticals Ltd, and Haleon US Holdings LLC ^107110111, and Class I device recalls from Percussionaire Corporation, Fresenius Kabi USA, and Datascope Corp. ^103104105.

What earns a Class I designation

The concrete precedents illustrate how the "reasonable probability of serious adverse health consequences or death" standard is applied.

Devices. Class I device recalls cluster around failures of life-supporting or therapy-delivery equipment ^169170172176:

• Defibtech, LLC recalled its RMU-2000 automated chest compression device after a motor problem that could cause compressions to stop, delaying therapy and risking patient injury or death ¹⁶⁹.
• Physio-Control, Inc. recalled LIFEPAK 20e defibrillator/monitors for power-related failures (unexpected power on/off, lock-up, failure to power) that could prevent therapy delivery in an emergency ¹⁷⁰.
• CareFusion 303, Inc. recalled Alaris System PC Unit Model 8015 pumps whose keypad could become unresponsive due to fluid ingress, interrupting or delaying infusions and titration for high-risk patients ¹⁷².
• Penumbra Inc. recalled its 3D Revascularization Device over a delivery-wire material issue that could cause wire breakage during a procedure ¹⁷⁶.

In each case, the common thread is that the failure mode can foreseeably cause serious injury or death, which is what separates Class I from a lower class ^169170172176.

Drugs. Class I drug recalls are dominated by sterility and contamination failures in injectable and compounded products ^149150151153:

• Baxter Healthcare Corporation recalled Heparin Sodium in 0.9% Sodium Chloride Injection for microbial contamination and out-of-limit endotoxin results ¹⁴⁹.
• US Compounding Inc recalled a docusate oral syringe product for microbial contamination with B. cepacia ¹⁵⁰.
• Central Admixture Pharmacy Services, Inc. recalled a stock TPN product for out-of-specification sterility results ¹⁵¹.
• SterRx, LLC recalled Sodium Bicarbonate in 5% Dextrose Injection after a third-party lab confirmed microbial contamination ¹⁵³.

Where actions sit below the recall threshold

The same public archive also carries actions that are deliberately not recalls. FDA groups "Recalls, Market Withdrawals, & Safety Alerts" together, and the records include voluntary market withdrawals, sometimes explicitly non-safety-related, distinguished from recalls taken because of a potential health or safety risk ^129130131132. That distinction in the records mirrors the regulatory definitions: a recall removes a violative, legally actionable product, while a market withdrawal addresses a minor or non-violation and does not carry the same reporting and classification consequences ^6092129131.